Global Health Limited · NSE:MEDANTA
Global Health — Q2 FY2027 Earnings Presentation
33 slides from Global Health's earnings presentation, Nov 3, 2026
Slide 1: Exchange filing cover letter
Limited Date: November 03, 2026 Ref:- GHL/2026-27/EXCH/72 The General Manager The Manager Dept. of Corporate Services Listing Department BSE Limited, National Stock Exchange of India Limited P J Towers, Dalal Street, Exchange Plaza, C-1, Block G, Mumbai - 400 001 Bandra Kurla Complex, Bandra (E), Mu
Slide 2: Investor Presentation Q2 and H1 FY2027
GLOBAL HEALTH LIMITED Dedicated to Life Investor Presentation Q2 and H1 FY2027 5 November 3, 2026 1
Slide 3: Disclaimer
Disclaimer I • This presentation, apart from historical information, contains some "forward-looking statements" including those describing the Company’s strategies, strategic direction, objectives, future prospects, estimates etc. These forward-looking statements involve a number of risks, uncertain
Slide 4: Contents
Contents 01 Q2 and H1 FY2027 Performance Update 02 Project Update and Capex Plan 03 Medanta’s Journey, Purpose and Model of Healthcare 04 Annexures 3
Slide 5: Q2 and H1 FY2027 Performance Update
01 Q2 and H1 FY2027 Performance Update 4
Slide 6: Q2 FY2027 performance summary
Q2 FY2027 performance summary Revenue Growth of 34% y-o-y driven by growth in patient volumes + meoama ~ ~ ~ ~ ~ ~ ~ Operating EBITDA1 INR 14,690 million INR 3,701 million INR 2,191 million ~ and Margins % Revenue from ~ operations Margins % Margin: 25.2% Margin: 14.9% ... PAT and Q2 FY26 Q2 FY26 ~
Slide 7: Q2 FY2027 performance summary
Q2 FY2027 performance summary Revenue Growth of 34% y-o-y, primarily led by increase in patient volumes Q2FY27 revenue from operations of INR 14,690 million; growth of 33.6% y-o-y Operating EBITDA grew 60.2 % y-o-y to INR 3,701 million with improved margins of 25.2% in Q2 FY27 compared to 21.0%
Slide 8: Q2 FY2027 Business update
Q2 FY2027 Business update Strengthening the Core and Building a Robust Pipeline for Sustainable Growth Capacity Expansion New Medical Equipment Deployed Noida: Added 49 beds; total operational capacity at 482 beds Gurugram Patna Lucknow: 25 beds added, taking total bed capacity to 803 beds Ran
Slide 9: Medanta Noida operational with 482 beds
Medanta Noida operational with 482 beds Noida operations demonstrating strong momentum, with EBITDA breakeven achieved during Q2 FY27 Revenue from operations (INR million) Operating EBITDA1 (INR million) 1,059 86 855 -49 525 341 -199 -236 37 -321 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 Q2 FY27 Q2 FY26 Q3 FY
Slide 10: Key operating metrics: Revenue and profitability
Key operating metrics: Revenue and profitability + meoama ~ ~ ~ Operating EBITDA in Q2 and H1 grew by 60% and 43% y-o-y, respectively ~ Revenue from operations (INR million) ~ ~ ~ C+30.2%~ + ~ 27,731 ~ ~ 21,301 ~ +33.6% + ~ 13,041 14,690 ~ 10,993 ~ H1 FY26 H1 FY27 ~ Q2 FY26 -= Q1 FY27 Q2 FY27 ~ ~ ~
Slide 11: Key operating metrics: Profitability and margin
Key operating metrics: Profitability and margin + meoama ~ ~ ~ Q2 PBT and PAT growth of 48% and 38% y-o-y, respectively ~ Profit before tax (INR million and margin %) ~ ~ ~ +24.5% + ~ 5,081 ~ 4,080 ~ ~ +47.6% + ~ 2,948 ~ 1,998 2,133 ~ ~ ~ ~ ~ ~ H1 FY26* H1 FY27 Q2 FY26* Q1 FY27 Q2 FY27 c=:>19.2% Pro
Slide 12: Key operating metrics: Volumes, occupancies, ALOS
Key operating metrics: Volumes, occupancies, ALOS Q2 FY27 witnessed 17% expansion in census bed capacity enabling strong IPD volume growth of 30% y-o-y Average census and occupied beds per day ALOS (days) +22.4% -5.3% -5.5% +21.8% +17.2% 3.04 2.88 3.06 2.87 2.89 3,076 3,037 3,115 2,573 2,658 1,987 1
Slide 13: Key operating metrics: ARPP and revenue mix
Key operating metrics: ARPP and revenue mix ARPP growth driven by change in case and payor mix ARPP* (INR Lakh) IPD Revenue mix by payor category** +1.5% +2.7% 2.01 2.04 2.01 2.02 2.06 56% 55% 56% 55% 56% 26% 27% 25% 26% 27% 11% 4% 11% 4% 12% 4% 11% 5% 10% 4% 3% 3% 3% 3% 3% H1 FY26 H1 FY27 Q2 FY26 Q
Slide 14: Diverse revenue mix
Diverse revenue1 mix Significant contribution from complex specialties Heart 20.8% 20.3% 20.7% 20.7% 19.8% Cancer 14.3% 13.9% 14.4% 13.5% 14.3% Digestive 11.7% 11.1% 12.1% 11.0% 11.2% Neuro 11.1% 11.0% 11.0% 11.2% 10.9% Kidney & Urology 7.5% 8.3% 7.4% 8.2% 8.5% Internal Medicine 5.8% 6.0% 5.8% 5.5%
Slide 15: Cluster 1 hospitals - Consistent Growth with Improved Margin
Cluster 1 hospitals - Consistent Growth with Improved Margin Growth in cluster-1 hospitals led by both patient volume and case mix change Cluster 1 hospitals – Gurugram, Indore and Ranchi Revenue from operations (INR million) Operating EBITDA (INR million and margin %) +14.0% +22.4% 15,708 +29.1% 13
Slide 16: Cluster 2 hospitals - Robust Growth with Improved Margin
Cluster 2 hospitals - Robust Growth with Improved Margin Inpatient volume growth of 52% and ARPP growth of 8% led to strong revenue and EBITDA growth Cluster 2 hospitals – Lucknow, Patna and Noida Revenue from operations (INR million) Operating EBITDA (INR million and margin %) +59.6% +73.2% 10,760
Slide 17: H1 FY2027 Balance sheet summary
H1 FY2027 Balance sheet summary Well capitalized balance sheet and strong EBITDA to cash flow conversion Key Highlights INR millions FY2023 FY2024 FY2025 FY2026 H1 FY2027 Gross Debt 8422 4,193 3,279 6,311 6,949 • Gross Debt increased by INR 638 million Cash and Cash Equivalents 13,114 11,913 11,402
Slide 18: Project Update and Capex Plan
02 Project Update and Capex Plan 17
Slide 19: On-going expansion projects
On-going expansion projects ~20% Capacity added in FY26. Planned bed capacity addition to drive sustainable growth Number of installed beds ~ 3,450 bed addition 490 bed addition +83.0% +13.4% 500 623 bed addition 400 650 - +20.5% 750 750 146 80 147 68 49,~ .----:--:--~ c400 T -------~ I - - ' 7,605
Slide 20: Estimated capex plan
Estimated capex plan Total capex of ~INR 62,390 million planned for next 4 - 5 years Project wise capex (INR mn) 1,939 3,000 9,820 325 5,898 8,986 5,398 62,390 ----------·-I 57,451 11,000 425 3,424 □12,175 Maintenance Lucknow, South Mumbai Pitampura, Guwahati Varanasi Indore Ghaziabad Medical Guest
Slide 21: Medanta's Journey, Purpose and Model of Healthcare
Medanta’s Journey, Purpose and 03 Model of Healthcare 20
Slide 22: Medanta was founded to bring a new type of healthcare to India
Medanta was founded to bring a new type of healthcare to India… … the human side of healthcare Healthcare is never only about science. It is also about the art of medicine – the human connection, putting the patient first, collaboration, the personal acts of empathy and the values that guide our dec
Slide 23: Growth from a single flagship hospital in Gurgaon
Growth from a single flagship hospital in Gurgaon… …to a network of 6 high quality hospitals across north India FY2026 MEDANTA 2025 HOSPITAL MEDANTA 2021 HOSPITAL NOIDA JAI PRABHA 550 Beds Ranchi Unit 2 2019 MEDANTA SPECIALTY 482 currently 110 Beds operational MEDANTA HOSPITAL Commenced including 98
Slide 24: From our flagship Medicity campus we have grown to 3,811 beds
~ d l\!,,,, meoa ma ~ From our flagship Medicity campus in Gurgaon, we have grown to 3,811 beds across 6 cities =mF ~ Largest private hospital beds in operation under one roof in Delhi (NCR), Uttar Pradesh and Bihar ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ Gurgaon LUCKNOW PATNA ~ 1,440 beds; 316 ICU beds 803 beds; 211 I
Slide 25: One of the largest private hospital chains in North and East India
One of the largest private hospital chains in North and East India Serving over 400 million people in the States with Medanta facilities Gurugram; Largest single location private hospital in with operational Delhi; ~1,150 bed addition bed capacity of 1,440 Our Network planned with 750 beds in Pitamp
Slide 26: Our Mission and Values
Our Mission and Values Embracing a new era and redefining our purpose Core Values Patient centric care: Foster a culture where every one of us MISSION is committed to care for patients and their caregivers Our mission is to deliver world class, patient ef!: Leadership and quality: Commit to deliveri
Slide 27: The Medanta Model of Healthcare
The Medanta Model of Healthcare Delivering the highest quality of medicine with care and compassion Exceptional clinical talent What it means for patients and caregivers? • Super specialized doctors provide the highest quality of care through a team based integrated approach Trust based compassionat
Slide 28: Medanta is well placed to deliver sustainable growth
Medanta is well placed to deliver sustainable growth… …while maintaining its core values of patient centric care and clinical leadership and quality CONTINUITY OF CARE TECHNOLOGY Extend clinical THOUGHT ADVANCEMENT services outside LEADERSHIP Use technology to hospital and ENHANCE Build on our impro
Slide 29: Annexures
04 Annexures 28
Slide 30: Annexure: Profit and Loss Statement
Annexure: Profit and Loss Statement Half Year Quarter Y-o-Y Y-o-Y INR million H1 FY2026 H1 FY2027 Q2FY2026 Q1FY2027 Q2FY2027 Growth % Growth % Revenue from operations 21,301 27,731 30.2% 10,993 13,041 14,690 33.6% Cost of materials consumed 4,946 6,156 24.5% 2,556 2,944 3,213 25.7% Employee benefits
Slide 31: Annexure: Operational Parameters
Annexure: Operational Parameters Year End Quarter Y-o-Y Y-o-Y Key metrics H1 FY2026 H1 FY2027 Q2FY2026 Q1FY2027 Q2FY2027 Growth % Growth % Total Beds 3,435 3,811 10.9% 3,435 3,737 3,811 10.9% Census Beds 2,573 3,076 19.6% 2,658 3,037 3,115 17.2% Occupied Bed Days 2,98,627 3,63,664 21.8% 1,55,729 1,7
Slide 32: Annexure: Abbreviations and Definitions
Annexure: Abbreviations and Definitions Abbreviations INR : Indian Rupee NABH : National Accreditation Board for Hospitals & Healthcare Providers NABL : National Accreditation Board for Testing and Calibration Laboratories JCI : Joint Commission International OPD : Out-Patient Department
Slide 33: Contact us
Contact us About Medanta Contact Details Founded by Dr. Naresh Trehan, a world-renowned cardiovascular and Gaurav Chugh Bhushan Khandelwal cardiothoracic surgeon who has been awarded the prestigious Head Investor Relations Investor Relations Padma Bhushan and the Padma Shri, the third- and fourth-hi